Cargando…

Tumor staging using 3.0 T multiparametric MRI in prostate cancer: impact on treatment decisions for radical radiotherapy

To assess and validate the incorporation of the multiparametric magnetic resonance imaging (mpMRI) tumour category (mT-category) to the conventional clinical tumour category (cT-category), in order to guide the radiotherapy (RT) treatment decisions in prostate cancer. In addition, to identify the cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Couñago, Felipe, del Cerro, Elia, Díaz-Gavela, Ana Aurora, Marcos, Francisco José, Recio, Manuel, Sanz-Rosa, David, Thuissard, Israel, Olaciregui, Karmele, Mateo, María, Cerezo, Laura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4684563/
https://www.ncbi.nlm.nih.gov/pubmed/26702378
http://dx.doi.org/10.1186/s40064-015-1596-0
_version_ 1782406194893160448
author Couñago, Felipe
del Cerro, Elia
Díaz-Gavela, Ana Aurora
Marcos, Francisco José
Recio, Manuel
Sanz-Rosa, David
Thuissard, Israel
Olaciregui, Karmele
Mateo, María
Cerezo, Laura
author_facet Couñago, Felipe
del Cerro, Elia
Díaz-Gavela, Ana Aurora
Marcos, Francisco José
Recio, Manuel
Sanz-Rosa, David
Thuissard, Israel
Olaciregui, Karmele
Mateo, María
Cerezo, Laura
author_sort Couñago, Felipe
collection PubMed
description To assess and validate the incorporation of the multiparametric magnetic resonance imaging (mpMRI) tumour category (mT-category) to the conventional clinical tumour category (cT-category), in order to guide the radiotherapy (RT) treatment decisions in prostate cancer. In addition, to identify the clinical factors associated to the technique reliability. mpMRI was performed in 274 prostate cancer patients in order to refine the treatment decisions according to PSA, Gleason Score (GS) and cT-category. Comparisons between the cT and mT-category were performed, as well as the impact on the RT treatment [target volume, doses and hormonal therapy (HT)] independently if it was finally performed. Changes in HT indication for intermediate risk were also analyzed. mpMRI validation was performed with pathological staging (n = 90 patients finally decided to join surgery). The mpMRI upstaging range was 86–94 % for any PSA value or GS. Following mpMRI, 32.8 % of the patients (90/274) were assigned to a different risk group. Compared to cT-category, mpMRI identified more intermediate-risk (46.4 vs. 59.5 %) and high-risk (19.0 vs. 28.8 %) prostate cancer patients. This resulted in a higher indication (p < 0.05) of seminal vesicle irradiation (63.5 vs. 70.0 %), inclusion of any extracapsular disease (T3–T4) within the target volume (1.8 vs. 18.2 %), higher doses (65.3 vs. 88.3 %) and HT associated to RT (45.6 vs. 62.4 %). Global accuracy for mpMRI was higher compared to DRE/TRUS (8.9 vs. 71.1 %, p < 0.05). mpMRI reliability was independent of PSA or GS. mpMRI tumor staging significantly modified the RT treatment decisions in all prostate cancer risk groups.
format Online
Article
Text
id pubmed-4684563
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-46845632015-12-23 Tumor staging using 3.0 T multiparametric MRI in prostate cancer: impact on treatment decisions for radical radiotherapy Couñago, Felipe del Cerro, Elia Díaz-Gavela, Ana Aurora Marcos, Francisco José Recio, Manuel Sanz-Rosa, David Thuissard, Israel Olaciregui, Karmele Mateo, María Cerezo, Laura Springerplus Research To assess and validate the incorporation of the multiparametric magnetic resonance imaging (mpMRI) tumour category (mT-category) to the conventional clinical tumour category (cT-category), in order to guide the radiotherapy (RT) treatment decisions in prostate cancer. In addition, to identify the clinical factors associated to the technique reliability. mpMRI was performed in 274 prostate cancer patients in order to refine the treatment decisions according to PSA, Gleason Score (GS) and cT-category. Comparisons between the cT and mT-category were performed, as well as the impact on the RT treatment [target volume, doses and hormonal therapy (HT)] independently if it was finally performed. Changes in HT indication for intermediate risk were also analyzed. mpMRI validation was performed with pathological staging (n = 90 patients finally decided to join surgery). The mpMRI upstaging range was 86–94 % for any PSA value or GS. Following mpMRI, 32.8 % of the patients (90/274) were assigned to a different risk group. Compared to cT-category, mpMRI identified more intermediate-risk (46.4 vs. 59.5 %) and high-risk (19.0 vs. 28.8 %) prostate cancer patients. This resulted in a higher indication (p < 0.05) of seminal vesicle irradiation (63.5 vs. 70.0 %), inclusion of any extracapsular disease (T3–T4) within the target volume (1.8 vs. 18.2 %), higher doses (65.3 vs. 88.3 %) and HT associated to RT (45.6 vs. 62.4 %). Global accuracy for mpMRI was higher compared to DRE/TRUS (8.9 vs. 71.1 %, p < 0.05). mpMRI reliability was independent of PSA or GS. mpMRI tumor staging significantly modified the RT treatment decisions in all prostate cancer risk groups. Springer International Publishing 2015-12-18 /pmc/articles/PMC4684563/ /pubmed/26702378 http://dx.doi.org/10.1186/s40064-015-1596-0 Text en © Couñago et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Research
Couñago, Felipe
del Cerro, Elia
Díaz-Gavela, Ana Aurora
Marcos, Francisco José
Recio, Manuel
Sanz-Rosa, David
Thuissard, Israel
Olaciregui, Karmele
Mateo, María
Cerezo, Laura
Tumor staging using 3.0 T multiparametric MRI in prostate cancer: impact on treatment decisions for radical radiotherapy
title Tumor staging using 3.0 T multiparametric MRI in prostate cancer: impact on treatment decisions for radical radiotherapy
title_full Tumor staging using 3.0 T multiparametric MRI in prostate cancer: impact on treatment decisions for radical radiotherapy
title_fullStr Tumor staging using 3.0 T multiparametric MRI in prostate cancer: impact on treatment decisions for radical radiotherapy
title_full_unstemmed Tumor staging using 3.0 T multiparametric MRI in prostate cancer: impact on treatment decisions for radical radiotherapy
title_short Tumor staging using 3.0 T multiparametric MRI in prostate cancer: impact on treatment decisions for radical radiotherapy
title_sort tumor staging using 3.0 t multiparametric mri in prostate cancer: impact on treatment decisions for radical radiotherapy
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4684563/
https://www.ncbi.nlm.nih.gov/pubmed/26702378
http://dx.doi.org/10.1186/s40064-015-1596-0
work_keys_str_mv AT counagofelipe tumorstagingusing30tmultiparametricmriinprostatecancerimpactontreatmentdecisionsforradicalradiotherapy
AT delcerroelia tumorstagingusing30tmultiparametricmriinprostatecancerimpactontreatmentdecisionsforradicalradiotherapy
AT diazgavelaanaaurora tumorstagingusing30tmultiparametricmriinprostatecancerimpactontreatmentdecisionsforradicalradiotherapy
AT marcosfranciscojose tumorstagingusing30tmultiparametricmriinprostatecancerimpactontreatmentdecisionsforradicalradiotherapy
AT reciomanuel tumorstagingusing30tmultiparametricmriinprostatecancerimpactontreatmentdecisionsforradicalradiotherapy
AT sanzrosadavid tumorstagingusing30tmultiparametricmriinprostatecancerimpactontreatmentdecisionsforradicalradiotherapy
AT thuissardisrael tumorstagingusing30tmultiparametricmriinprostatecancerimpactontreatmentdecisionsforradicalradiotherapy
AT olacireguikarmele tumorstagingusing30tmultiparametricmriinprostatecancerimpactontreatmentdecisionsforradicalradiotherapy
AT mateomaria tumorstagingusing30tmultiparametricmriinprostatecancerimpactontreatmentdecisionsforradicalradiotherapy
AT cerezolaura tumorstagingusing30tmultiparametricmriinprostatecancerimpactontreatmentdecisionsforradicalradiotherapy